Abstract:N6-methyladenosine (m6A) is the most abundant epigenetic modification of RNA, and its dysregulation drives aberrant transcription and translation programs that promote cancer occurrence and progression. Although defective gene regulation resulting from m6A often affects oncogenic and tumor-suppressing networks, m6A can also modulate tumor immunogenicity and immune cells involved in anti-tumor responses. Understanding this counterintuitive concept can aid the design of new drugs that target m6A to potentially improve the outcomes of cancer immunotherapies. Here, we provide an up-to-date and comprehensive overview of how m6A modifications intrinsically affect immune cells and how alterations in tumor cell m6A modifications extrinsically affect immune cell responses in the tumor microenvironment (TME). We also review strategies for modulating endogenous anti-tumor immunity and discuss the challenge of reshaping the TME. Strategies include: combining specific and efficient inhibitors against m6A regulators with immune checkpoint blockers; generating an effective programmable m6A gene-editing system that enables efficient manipulation of individual m6A sites; establishing an effective m6A modification system to enhance anti-tumor immune responses in T cells or natural killer cells; and using nanoparticles that specifically target tumor-associated macrophages (TAMs) to deliver messenger RNA or small interfering RNA of m6A-related molecules that repolarize TAMs, enabling them to remodel the TME. The goal of this review is to help the field understand how m6A modifications intrinsically and extrinsically shape immune responses in the TME so that better cancer immunotherapy can be designed and developed.

A new perspective on hematological malignancies: m6A modification in immune microenvironment

Interaction Between N6-methyladenosine Modification and the Tumor Microenvironment in Colorectal Cancer

The Regulation of N6‐methyladenosine Modification in PD‐L1‐induced Anti‐tumor Immunity

The emerging roles of N6-methyladenosine RNA methylation in human cancers

The Emerging Molecular Mechanism of M6a Modulators in Tumorigenesis and Cancer Progression

Role of m6A modifications in immune evasion and immunotherapy

Targeting the RNA M6a Modification for Cancer Immunotherapy

N6-Methyladenosine RNA Modification in the Tumor Immune Microenvironment: Novel Implications for Immunotherapy

N6-methyladenosine (m6a) RNA Modification in Tumor Immunity

N6-methyladenosine Modification: an Important Player in the Tumor Immune Microenvironment.

The Roles of M6a RNA Modifiers in Human Cancer

The Role of m6A Methylation in Tumor Immunity and Immune-Associated Disorder

Dual Effects of N6-methyladenosine on Cancer Progression and Immunotherapy

Roles and therapeutic implications of m6A modification in cancer immunotherapy

Manipulating the tumour immune microenvironment by N6-methyladenosine RNA modification

Role of N6-methyladenosine RNA modification in cancer

N6-Methyladenosine in Cancer Immunotherapy: an Undervalued Therapeutic Target

Physio-pathological Effects of N6-methyladenosine and Its Therapeutic Implications in Leukemia

The Importance of N6-methyladenosine Modification in Tumor Immunity and Immunotherapy.

N6-methyladenosine RNA Modifications: a Potential Therapeutic Target for AML

Regulation and application of m6A modification in tumor immunity